{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:57:21Z","timestamp":1790236641180,"version":"4.1.0"},"reference-count":137,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["JPM"],"abstract":"<jats:p>This review article aims to provide an overview of the pathophysiology, diagnosis, and contemporary management of cardiac amyloidosis (CA) as well as identify the knowledge gaps and areas of potential research. CA can be divided into two main groups: transthyretin cardiac amyloidosis (ATTR-CA) and light chain cardiac amyloidosis (AL-CA). The former further separates into wild-type transthyretin (ATTRwt) and hereditary transthyretin (ATTRv). African Americans, males, and people older than 75 are the most common demographics affected by this disease. Thanks to an increased understanding of this disease combined with better diagnostic techniques, there is growing awareness and a surge of clinical trials aimed at improving outcomes of CA. The diagnosis and treatment of CA is multifaceted and complex, relying on multiple imaging modalities and the cooperation of specialists to deliver effective treatments. While some disease-modifying agents have been introduced recently, their extraordinary cost limits their benefit or they are supported by limited evidence. Other agents are currently undergoing phase 3 trials. To date, there is scarce data surrounding optimal diagnostic and treatment strategies, including a potential role for combination therapies. Critically, it is imperative that physicians develop close relationships with the patient that addresses not only their individual health needs but also their unique psychosocial situation. Therefore, more clinical trials, protocols and patient resources are needed to better inform and guide providers managing these complex patient needs.<\/jats:p>","DOI":"10.3390\/jpm15100472","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T08:20:28Z","timestamp":1759393228000},"page":"472","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cardiac Amyloidosis: Tribulations and New Frontiers"],"prefix":"10.3390","volume":"15","author":[{"given":"Darren M.","family":"Nguyen","sequence":"first","affiliation":[{"name":"Internal Medicine, University of Nevada Las Vegas, Kirk Kerkorian School of Medicine, Las Vegas, NV 89102, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0379-3811","authenticated-orcid":false,"given":"Noyan","family":"Ramazani","sequence":"additional","affiliation":[{"name":"Internal Medicine, University of Nevada Las Vegas, Kirk Kerkorian School of Medicine, Las Vegas, NV 89102, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurpreet","family":"Sodhi","sequence":"additional","affiliation":[{"name":"Advanced Heart Failure and Transplantation, Sutter Sacramento Medical Center, California Northstate University, School of Medicine, Elk Grove, CA 95758, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir","family":"Tak","sequence":"additional","affiliation":[{"name":"Department of Cardiology, VA Southern Nevada Healthcare System, North Las Vegas, NV 89086, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1002\/ehf2.13360","article-title":"Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy","volume":"8","author":"Devesa","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Robles","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e005407","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of Cardiac Amyloidosis\u2013Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States","volume":"12","author":"Gilstrap","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-Sequence Transthyretin (Isoleucine 122) in Late-Onset Cardiac Amyloidosis in Black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","article-title":"Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14\u2009333 African\u2013Americans","volume":"3","author":"Jacobson","year":"2015","journal-title":"Amyloid"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/eurheartj\/ehz173","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: An insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"43","author":"Damy","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/jnnp.59.1.45","article-title":"Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: A clinical, genetic, and epidemiological study","volume":"59","author":"Reilly","year":"1995","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","article-title":"Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant","volume":"33","author":"Sattianayagam","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3233\/JND-210656","article-title":"Hereditary transthyretin amyloidosis- clinical and genetic characteristics of a multiracial South-East Asian cohort in Singapore","volume":"8","author":"Chen","year":"2021","journal-title":"J. Neuromuscul. Disord."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/acn3.51328","article-title":"Hereditary transthyretin amyloidosis in mainland China: A unicentric retrospective study","volume":"8","author":"Du","year":"2021","journal-title":"Ann. Transl. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ikura, H., Endo, J., Kitakata, H., Moriyama, H., Sano, M., and Fukuda, K. (2022). Molecular mechanism of pathogenesis and treatment strategies for al amyloidosis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23116336"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1182\/blood-2023-181635","article-title":"Prevalence, Incidence, and Characterization of light chain amyloidosis in the USA: A real-world analysis utilizing electronic health records (EHR)","volume":"142","author":"Laires","year":"2023","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-020-00385-0","article-title":"Race\/ethnicity in systemic AL amyloidosis: Perspectives on disease and outcome disparities","volume":"10","author":"Staron","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13023-022-02414-6","article-title":"Global epidemiology of amyloid light-chain amyloidosis","volume":"17","author":"Kumar","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"752","DOI":"10.4070\/kcj.2013.43.11.752","article-title":"Incidence, Diagnosis and Prognosis of Cardiac Amyloidosis","volume":"43","author":"Lee","year":"2013","journal-title":"Korean Circ. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00392-019-01490-2","article-title":"When and how do patients with cardiac amyloidosis die?","volume":"109","author":"Escher","year":"2020","journal-title":"Clin. Res. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1002\/ehf2.12884","article-title":"Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan","volume":"5","author":"Yamada","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e000098","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1017\/cjn.2020.271","article-title":"Utility of Neuropathy Screening for Wild-Type Transthyretin Amyloidosis Patients","volume":"5","author":"Russell","year":"2021","journal-title":"Can. J. Neurol. Sci.\/J. Can. Des. Sci. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4253\/wjge.v13.i1.1","article-title":"Gastrointestinal amyloidosis: A focused review","volume":"13","author":"Dahiya","year":"2021","journal-title":"World J. Gastrointest. Endosc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e13229","DOI":"10.1111\/nmo.13229","article-title":"Clinical implications of gastrointestinal symptoms in systemic amyloidosis","volume":"30","author":"Yen","year":"2018","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1111\/j.1572-0241.2003.07695.x","article-title":"Rapid intestinal transit as a primary cause of severe chronic diarrhea in patients with amyloidosis","volume":"98","author":"Guirl","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/ndt\/18.3.532","article-title":"Familial ATTR amyloidosis: Microalbuminuria as a predictor of symptomatic disease and clinical nephropathy","volume":"18","author":"Lobato","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/13506120410001673884","article-title":"End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: Presentation, survival and prognostic factors","volume":"11","author":"Lobato","year":"2004","journal-title":"Amyloid"},{"key":"ref_26","first-page":"351","article-title":"Management of Arrhythmias in Cardiac Amyloidosis","volume":"4","author":"Giancaterino","year":"2020","journal-title":"J. Am. Coll. Cardiol. EP"},{"key":"ref_27","first-page":"147","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: Prevalence, incidence, risk factors and prognostic role","volume":"3","author":"Longhi","year":"2014","journal-title":"Amyloid"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Briasoulis, A., Kourek, C., Papamichail, A., Loritis, K., Bampatsias, D., Repasos, E., Xanthopoulos, A., Tsougos, E., and Paraskevaidis, I. (2023). Arrhythmias in patients with cardiac amyloidosis: A comprehensive review on clinical management and devices. J. Cardiovasc. Dev. Dis., 10.","DOI":"10.3390\/jcdd10080337"},{"key":"ref_29","first-page":"200271","article-title":"Cardiac amyloidosis red flags: What all the cardiologist have to know","volume":"21","author":"Malobert","year":"2024","journal-title":"Int. J. Cardiol. Cardiovasc. Risk Prev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","article-title":"Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review","volume":"10","author":"Rozenbaum","year":"2021","journal-title":"Cardiol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/anec.12018","article-title":"The findings of electrocardiography in patients with cardiac amyloidosis","volume":"18","author":"Cheng","year":"2013","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.amjcard.2014.07.026","article-title":"Prevalence and Prognostic Significance of Low QRS Voltage Among the Three Main Types of Cardiac Amyloidosis","volume":"114","author":"Cyrille","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5603\/CJ.a2021.0085","article-title":"Echocardiographic markers of cardiac amyloidosis in patients with heart failure and left ventricular hypertrophy","volume":"30","author":"Polo","year":"2023","journal-title":"Cardiol. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.pcad.2018.11.001","article-title":"Is speckle tracking imaging ready for prime time in current echo clinical practice?","volume":"61","author":"Luis","year":"2018","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"19","author":"Phelon","year":"2012","journal-title":"Heart"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Leitman, M., and Tyomkin, V. (2024). Apical Sparing in Routine Echocardiography: Occurrence and Clinical Significance. J. Cardiovasc. Dev. Dis., 11.","DOI":"10.3390\/jcdd11090262"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jcmg.2018.07.005","article-title":"Research to Practice: Assessment of Left Ventricular Global Longitudinal Strain for Surveillance of Cancer Chemotherapeutic-Related Cardiac Dysfunction","volume":"8","author":"Yang","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e005588","DOI":"10.1161\/CIRCIMAGING.116.005588","article-title":"Echo Parameters for Differential Diagnosis in Cardiac Amyloidosis: A Head-to-Head Comparison of Deformation and Nondeformation Parameters","volume":"10","author":"Pagourelias","year":"2017","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","article-title":"Cardiovascular magnetic resonance in cardiac amyloidosis","volume":"111","author":"Maciera","year":"2005","journal-title":"Circulation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1081\/JCMR-120022267","article-title":"How we perform delayed enhancement imaging","volume":"5","author":"Kim","year":"2003","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3941\/jrcr.v9i6.2328","article-title":"Delayed Myocardial Enhancement in Cardiac Magnetic Resonance Imaging","volume":"9","author":"Franco","year":"2015","journal-title":"J. Radiol. Case Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1532-429X-12-69","article-title":"Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold","volume":"12","author":"Piechnik","year":"2010","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_43","first-page":"488","article-title":"Noncontrast T1 Mapping for the Diagnosis of Cardiac Amyloidosis","volume":"6","author":"Karamitsos","year":"2013","journal-title":"J. Am. Coll. Cardiol. Cardiovasc. Imaging"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12968-016-0308-4","article-title":"Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: A comprehensive review","volume":"18","author":"Haaf","year":"2017","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and Extracellular Volume in Transthyretin Amyloidosis","volume":"12","author":"Kotecha","year":"2019","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Korthals, D., Chatzantonis, G., Bietenbeck, M., Meier, C., Stalling, P., and Yilmaz, A. (2021). CMR-based T1-mapping offers superior diagnostic value compared to longitudinal strain-based assessment of relative apical sparing in cardiac amyloidosis. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-94650-2"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e017427","DOI":"10.1161\/CIRCIMAGING.124.017427","article-title":"MRI-Extracellular Volume Fraction Versus Histological Amyloid Load in Cardiac Amyloidosis: The Importance of T2 Mapping","volume":"18","author":"Kidoh","year":"2025","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Grazzini, G., Pradella, S., Bani, R., Fornaciari, C., Cappelli, F., Perfetto, F., Cozzi, D., Giovannelli, S., Sica, G., and Miele, V. (2024). The Role of T2 Mapping in Cardiac Amyloidosis. Diagnostics, 14.","DOI":"10.3390\/diagnostics14101048"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12968-018-0478-3","article-title":"Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis","volume":"20","author":"Ridouani","year":"2018","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Mori, A., Saito, Y., Nakamura, K., Iida, T., Akagi, S., Yoshida, M., Taniyama, M., Miyoshi, T., and Ito, H. (2023). Microcalcification and 99mTc-Pyrophosphate Uptake without Increased Bone Metabolism in Cardiac Tissue from Patients with Transthyretin Cardiac Amyloidosis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24031921"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e010249","DOI":"10.1161\/CIRCIMAGING.119.010249","article-title":"Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis","volume":"13","author":"Masri","year":"2020","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12350-020-02328-5","article-title":"Comparison of planar with tomographic pyrophosphate scintigraphy for transthyretin cardiac amyloidosis: Perils and pitfalls","volume":"28","author":"Asif","year":"2021","journal-title":"J. Nucl. Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2019.08.001","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2\u2014Evidence Base and Standardized Methods of Imaging","volume":"25","author":"Dorbala","year":"2019","journal-title":"J. Card. Fail."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"99mTc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ. Cardiovasc. Imaging."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study","volume":"12","author":"Long","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"ref_57","first-page":"117","article-title":"AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management","volume":"1","author":"Witteles","year":"2019","journal-title":"J. Am. Coll. Cardiol. CardioOncology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13506129.2016.1257986","article-title":"Amyloid fibril proteins and amyloidosis: Chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines","volume":"23","author":"Sipe","year":"2016","journal-title":"Amyloid"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: A report of the american college of cardiology solution set oversight committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_60","first-page":"127","article-title":"Evidence of Concurrent Light Chain and Transthyretin Cardiac Amyloidosis in 2 Patients","volume":"2","author":"Donnelly","year":"2020","journal-title":"J. Am. Coll. Cardiol. CardioOncology"},{"key":"ref_61","first-page":"598","article-title":"ATTR Cardiomyopathy Meets Multiple Myeloma","volume":"3","author":"Kanelidis","year":"2021","journal-title":"J. Am. Coll. Cardiol. CardioOncology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-019-0193-9","article-title":"Two types of amyloidosis presenting in a single patient: A case series","volume":"9","author":"Sidiqi","year":"2019","journal-title":"Nat. Blood Cancer J."},{"key":"ref_63","first-page":"1368","article-title":"How to Image Cardiac Amyloidosis: A Practical Approach","volume":"13","author":"Dorbala","year":"2020","journal-title":"J. Am. Coll. Cardiol. Cardiovasc. Imaging"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jelectrocard.2008.06.021","article-title":"Low QRS voltage and its causes","volume":"41","author":"Madias","year":"2008","journal-title":"J. Electrocardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jacc.2012.04.043","article-title":"Longitudinal Left Ventricular Function for Prediction of Survival in Systemic Light-Chain Amyloidosis: Incremental Value Compared with Clinical and Biochemical Markers","volume":"12","author":"Buss","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_66","first-page":"398","article-title":"Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System","volume":"4","author":"Williams","year":"2017","journal-title":"J. Am. Coll. Cardiol. Imaging"},{"key":"ref_67","unstructured":"Ghadimi, M., and Sapra, A. (2019). Magnetic Resonance Imaging Contraindications, StatPearls."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"24","author":"Quarta","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/07853890.2017.1304649","article-title":"Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): The consequence of failure of early recognition","volume":"49","author":"Muchtar","year":"2017","journal-title":"Ann. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamacardio.2023.4147","article-title":"Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: A post hoc analysis of the ATTR-ACT randomized clinical trial","volume":"9","author":"Shah","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e008193","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy","volume":"15","author":"Elliott","year":"2021","journal-title":"Circ. Heart Fail."},{"key":"ref_74","unstructured":"Canadian Agency for Drugs and Technologies in Health Pharmacoeconomic Review Report: Tafamidis (Vyndaqel), Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK563701\/."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR Cardiac Amyloidosis","volume":"18","author":"Helmke","year":"2012","journal-title":"Congest. Heart Fail."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1016\/j.febslet.2009.10.062","article-title":"Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity","volume":"583","author":"Ferreira","year":"2009","journal-title":"FEBS Lett."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00392-012-0463-z","article-title":"Green tea halts progression of cardiac transthyretin amyloidosis: An observational report","volume":"101","author":"Kristen","year":"2012","journal-title":"Clin. Res. Cardiol."},{"key":"ref_79","unstructured":"Canadian Agency for Drugs and Technologies in Health Pharmacoeconomic Review Report: Patisiran (Onpattro), Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK549697\/."},{"key":"ref_80","unstructured":"Canadian Agency for Drugs and Technologies in Health Pharmacoeconomic Review Report: Inotersen (Tegsedi), Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK558353\/."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12872-025-04653-4","article-title":"The efficacy and safety of specific therapies for cardiac Transthyretin-mediated amyloidosis: A systematic review and meta-analysis of randomized trials","volume":"25","author":"Prata","year":"2025","journal-title":"BMC Cardiovasc. Discord."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/mus.27675","article-title":"Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEURO-TTR trial","volume":"66","author":"Karam","year":"2022","journal-title":"Muscle Nerve"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis","volume":"387","author":"Maurer","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_85","unstructured":"Alnylam Alnylam Announces Receipt of Complete Response Letter from, U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis, Available online: https:\/\/investors.alnylam.com\/press-release?id=27741."},{"key":"ref_86","unstructured":"Cllinicaltrails.gov HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients with Hereditary Transthyretin Amyloidosis (ATTRv Amyloidosis), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03759379?term=helios&cond=cardiac%20amyloidosis&rank=1."},{"key":"ref_87","unstructured":"Clinicaltrials.gov HELIOS-B: A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04153149."},{"key":"ref_88","unstructured":"Food Drug Administration Developing Products for Rare Diseases and Conditions, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=827521."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"J. Am. Med. Assoc."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/FJC.0000000000001478","article-title":"Recent Progress in the Development and Clinical Application of New Drugs for Transthyretin Cardiac Amyloidosis","volume":"82","author":"Zhou","year":"2023","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_91","unstructured":"Rare Disease Advisor N1006 Has Acceptable Safety Profile in Patients with, A.T.T.R.-C.M. Available online: https:\/\/www.rarediseaseadvisor.com\/news\/n1006-safety-profile-transthyretin-amyloid-cardiomyopathy\/."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid","volume":"389","author":"Siepen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A Single Administration of CRISPR\/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing","volume":"9","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"6","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa2412309","article-title":"CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy","volume":"319","author":"Fontana","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1093\/nar\/gku402","article-title":"CRISPR\/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences","volume":"11","author":"Lin","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-Nanoparticle-Based Delivery of CRISPR\/Cas9 Genome-Editing Components","volume":"6","author":"Kazemian","year":"2022","journal-title":"Mol. Pharm."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_99","unstructured":"ClinicalTrials.gov MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06128629."},{"key":"ref_100","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial Fibrillation in Transthyretin Cardiac Amyloidosis","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC. Clin. Electrophysiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1002\/ehf2.14082","article-title":"Electrical cardioversion of atrial arrhythmias with cardiac amyloidosis in the era of direct oral anticogulants","volume":"9","author":"Touboul","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/pace.13992","article-title":"Catheter ablation of atrial fibrillation in cardiac amyloidosis","volume":"43","author":"Rehorn","year":"2020","journal-title":"Pacing. Clin. Electrophysiol."},{"key":"ref_108","first-page":"772","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: A systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"Eur. Soc. Cardiol."},{"key":"ref_109","first-page":"1473","article-title":"No Association Between CHADS-VASc Score and Left Atrial Appendage Thrombus in Patients With Transthyretin Amyloidosis","volume":"5","author":"Donnellan","year":"2019","journal-title":"J. Am. Coll. Cardiol. EP"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","article-title":"Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death","volume":"5","author":"Kristen","year":"2008","journal-title":"Heart Rhythm."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","article-title":"Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis","volume":"11","author":"Varr","year":"2013","journal-title":"Heart Rhythm."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable Cardioverter Defibrillators in Patients with Cardiac Amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_113","first-page":"e272","article-title":"2017 AHA\/ACC\/HRS Guideline for Management of Patients with Ventricular Arrhythmias and:: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"13","author":"Stevenson","year":"2018","journal-title":"Circulation"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/ejhf.2533","article-title":"Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis","volume":"24","author":"Porcari","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/heartjnl-2022-322315","article-title":"Predictors and outcomes of pacemaker implantation in patients with cardiac amyloidosis","volume":"110","author":"Saturi","year":"2024","journal-title":"Heart"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"101912","DOI":"10.1016\/j.cpcardiol.2023.101912","article-title":"Bradyarrhythmias in Cardiac Amyloidosis and Role of Pacemaker","volume":"48","author":"Bukhari","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e017335","DOI":"10.1161\/JAHA.120.017335","article-title":"Cardiac Resynchronization Therapy for Transthyretin Cardiac Amyloidosis","volume":"9","author":"Donnellan","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ehf2.13663","article-title":"Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis","volume":"9","author":"Fischer","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_119","first-page":"6105","article-title":"Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis","volume":"118","author":"Cordes","year":"2012","journal-title":"J. Am. Cancer Soc."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/ajh.25566","article-title":"Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis","volume":"94","author":"Sidana","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2021.2002841","article-title":"Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines","volume":"29","author":"Sanchorawala","year":"2022","journal-title":"Amyloid"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","article-title":"Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group","volume":"30","author":"Wechalekar","year":"2022","journal-title":"Amyloid"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"20","author":"Sanchorawala","year":"2015","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","article-title":"AL amyloidosis: Current chemotherapy and immune therapy treatment strategies: Jacc: CardioOncology state-of-the-art review","volume":"3","author":"Bianchi","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","article-title":"The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update","volume":"35","author":"Mehra","year":"2016","journal-title":"J. Heart Lung Transplant."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.healun.2017.07.019","article-title":"The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report\u20142017; Focus Theme: Allograft ischemic time","volume":"10","author":"Lund","year":"2017","journal-title":"J. Heart Lung Transplant."},{"key":"ref_127","first-page":"461","article-title":"Outcomes in Patients with Cardiac Amyloidosis Undergoing Heart Transplantation","volume":"6","author":"Barrett","year":"2020","journal-title":"Heart Fail."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/WCO.0000000000000290","article-title":"Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis","volume":"29","author":"Obici","year":"2016","journal-title":"Curr. Opin. Neurol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/mus.25210","article-title":"Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy","volume":"54","author":"Schmidt","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/13506129.2011.569782","article-title":"Spinal cord stimulation markedly ameliorated refractory neuropathic pain in transthyretin Val30Met familial amyloid polyneuropathy","volume":"18","author":"Miyazaki","year":"2011","journal-title":"Amyloid"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2215\/CJN.02470607","article-title":"Presentation and Outcome of Patients with Systemic Amyloidosis Undergoing Dialysis","volume":"3","author":"Guery","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-022-00714-5","article-title":"Outcomes of renal transplantation in patients with AL amyloidosis: An international collaboration through The International Kidney and Monoclonal Gammopathy Research Group","volume":"12","author":"Havasi","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.kint.2018.09.021","article-title":"Long-term outcome of kidney transplantation in AL amyloidosis","volume":"95","author":"Stern","year":"2019","journal-title":"Kidney Int."},{"key":"ref_134","unstructured":"Dispenzieri, A. Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05557162?cond=cardiac%20amyloidosis&page=2&rank=11."},{"key":"ref_135","unstructured":"Ouyang, D. Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05139797?cond=cardiac%20amyloidosis&term=artificial%20intelligence&rank=1."},{"key":"ref_136","first-page":"EVIDoa2200003","article-title":"Real-Time Artificial Intelligence\u2013Based Optical Diagnosis of Neoplastic Polyps during Colonoscopy","volume":"1","author":"Barua","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_137","first-page":"1376","article-title":"Clinical Implementation of an AI Early Warning System Algorithm: Lessons Learned","volume":"25","author":"Meehan","year":"2024","journal-title":"Stud. Health Technol. Inform."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/10\/472\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T08:31:47Z","timestamp":1759393907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/10\/472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":137,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["jpm15100472"],"URL":"https:\/\/doi.org\/10.3390\/jpm15100472","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]}}}